|
gptkbp:instanceOf
|
gptkb:drug
hypnotic
imidazopyridine
|
|
gptkbp:ATCCode
|
N05CF02
|
|
gptkbp:bioavailability
|
70%
|
|
gptkbp:brand
|
gptkb:Ambien
gptkb:Edluar
gptkb:Stilnox
gptkb:Zolpimist
gptkb:Intermezzo
|
|
gptkbp:CASNumber
|
82626-48-0
|
|
gptkbp:chemicalClass
|
imidazopyridine
|
|
gptkbp:contraindication
|
sleep apnea
severe liver impairment
|
|
gptkbp:controlledSubstanceSchedule
|
Schedule IV (US)
|
|
gptkbp:discoveredBy
|
gptkb:Synthelabo
|
|
gptkbp:eliminationHalfLife
|
2-3 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasMolecularFormula
|
C19H21N3O
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
zolpidem
|
|
gptkbp:introducedIn
|
1986
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
GABA-A receptor agonist
|
|
gptkbp:meltingPoint
|
195-196°C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
92.5%
|
|
gptkbp:PubChem_CID
|
5732
DB00425
|
|
gptkbp:riskFactor
|
abuse
withdrawal
dependence
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:center
nausea
hallucination
dizziness
headache
drowsiness
|
|
gptkbp:synonym
|
N,N-dimethyl-2-(6-methyl-2-p-tolylimidazo[1,2-a]pyridin-3-yl)acetamide
|
|
gptkbp:UNII
|
7K383OQI23
|
|
gptkbp:usedFor
|
insomnia
|
|
gptkbp:bfsParent
|
gptkb:CYP3A4
|
|
gptkbp:bfsLayer
|
5
|